Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy

MLA

Ben M. Lomaestro, et al. “Comparative Incidence and Excess Risk of Acute Kidney Injury in Hospitalised Patients Receiving Vancomycin and Piperacillin/Tazobactam in Combination or as Monotherapy.” International Journal of Antimicrobial Agents, vol. 52, Nov. 2018, pp. 643–50. EBSCOhost, https://doi.org/10.1016/j.ijantimicag.2018.08.001.

APA

Ben M. Lomaestro, Ellis H. Tobin, Joseph J. Carreno, Tori Smiraglia, & Christopher Hunter. (2018). Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. International Journal of Antimicrobial Agents, 52, 643–650. https://doi.org/10.1016/j.ijantimicag.2018.08.001

Chicago

Ben M. Lomaestro, Ellis H. Tobin, Joseph J. Carreno, Tori Smiraglia, and Christopher Hunter. 2018. “Comparative Incidence and Excess Risk of Acute Kidney Injury in Hospitalised Patients Receiving Vancomycin and Piperacillin/Tazobactam in Combination or as Monotherapy.” International Journal of Antimicrobial Agents 52 (November): 643–50. doi:10.1016/j.ijantimicag.2018.08.001.